Lake Street Advisors Group LLC Boosts Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Lake Street Advisors Group LLC boosted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 99,168 shares of the company’s stock after acquiring an additional 2,893 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Hims & Hers Health were worth $932,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Marshall Wace LLP increased its position in Hims & Hers Health by 99.4% in the fourth quarter. Marshall Wace LLP now owns 4,487,038 shares of the company’s stock worth $28,762,000 after buying an additional 2,236,609 shares in the last quarter. Millennium Management LLC increased its position in Hims & Hers Health by 145.8% in the fourth quarter. Millennium Management LLC now owns 3,524,750 shares of the company’s stock worth $22,594,000 after buying an additional 2,090,833 shares in the last quarter. State Street Corp increased its position in Hims & Hers Health by 16.3% in the third quarter. State Street Corp now owns 3,021,045 shares of the company’s stock worth $16,857,000 after buying an additional 423,361 shares in the last quarter. Geode Capital Management LLC increased its position in Hims & Hers Health by 3.5% in the first quarter. Geode Capital Management LLC now owns 2,271,074 shares of the company’s stock worth $22,529,000 after buying an additional 77,801 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Hims & Hers Health by 16.4% in the second quarter. Renaissance Technologies LLC now owns 1,959,100 shares of the company’s stock worth $8,875,000 after buying an additional 276,500 shares in the last quarter. Hedge funds and other institutional investors own 61.45% of the company’s stock.

Hims & Hers Health Stock Down 3.1 %

Hims & Hers Health stock traded down $0.24 during midday trading on Friday, reaching $7.47. 2,347,040 shares of the stock traded hands, compared to its average volume of 3,311,999. The stock’s fifty day moving average is $6.39 and its 200-day moving average is $7.84. Hims & Hers Health, Inc. has a 12 month low of $5.61 and a 12 month high of $12.34. The stock has a market cap of $1.58 billion, a P/E ratio of -43.88 and a beta of 0.55.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The company had revenue of $226.70 million during the quarter, compared to the consensus estimate of $220.08 million. Hims & Hers Health had a negative net margin of 4.50% and a negative return on equity of 11.22%. Hims & Hers Health’s revenue for the quarter was up 56.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.09) earnings per share. On average, equities analysts predict that Hims & Hers Health, Inc. will post -0.13 EPS for the current fiscal year.

Insider Activity

In other news, insider Irene Becklund sold 10,596 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $6.31, for a total value of $66,860.76. Following the completion of the sale, the insider now directly owns 5,494 shares of the company’s stock, valued at approximately $34,667.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Irene Becklund sold 10,596 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $6.31, for a total value of $66,860.76. Following the sale, the insider now directly owns 5,494 shares in the company, valued at $34,667.14. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Lynne Chou O’keefe sold 10,045 shares of the stock in a transaction that occurred on Tuesday, September 19th. The stock was sold at an average price of $6.31, for a total value of $63,383.95. The disclosure for this sale can be found here. Insiders sold 79,798 shares of company stock valued at $523,299 in the last ninety days. Insiders own 31.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HIMS. Piper Sandler dropped their price objective on Hims & Hers Health from $11.00 to $10.00 in a research note on Tuesday, August 8th. TD Cowen began coverage on Hims & Hers Health in a research note on Friday, July 28th. They issued an “outperform” rating and a $11.00 price objective for the company. Credit Suisse Group reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, August 8th. Finally, Truist Financial dropped their price objective on Hims & Hers Health from $12.00 to $10.00 and set a “hold” rating for the company in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average price target of $12.36.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.